Tigecycline's Link to Liver Enzyme Elevations
Tigecycline, a glycylcycline antibiotic used for complicated infections, causes increases in liver enzymes like ALT and AST in 10-20% of patients, with severe cases (levels >10x upper limit of normal) in under 1%.[1][2] These changes are typically asymptomatic and reversible after stopping the drug.
How Tigecycline Triggers Enzyme Increases
Tigecycline disrupts bacterial protein synthesis by binding the 30S ribosomal subunit, but in humans, it induces mild, dose-dependent hepatotoxicity via hepatocyte stress. It inhibits bile salt export pump (BSEP), leading to cholestasis-like effects and elevated alkaline phosphatase alongside transaminases.[3] Animal studies show tigecycline concentrates in liver tissue (up to 7x plasma levels), causing oxidative stress and mitochondrial dysfunction, which elevate enzymes without necrosis.[4]
Risk Factors and Patient Patterns
Higher risks occur with doses >100 mg/day, prolonged use (>14 days), or in patients with baseline liver issues, obesity, or concurrent hepatotoxins like acetaminophen.[2][5] IV administration peaks enzyme rises at days 7-14, resolving in 7-10 days post-treatment. No direct link to liver failure in monotherapy, but monitor in ICU settings where multidrug exposure is common.
Clinical Monitoring and Management
Guidelines recommend baseline and weekly LFTs during therapy; hold tigecycline if ALT/AST >5x ULN or bilirubin >2x ULN.[1][6] Most cases (93%) resolve without intervention. Alternatives like eravacycline show lower hepatotoxicity rates (ALT 3-5%).[7]
When Does Recovery Happen?
Enzyme levels normalize in 70-90% of cases within 2 weeks of discontinuation, faster with hydration and avoiding alcohol.[2][4] Persistent elevations beyond 4 weeks warrant imaging or biopsy to rule out unrelated causes.
Sources
[1]: FDA Tigecycline Label
[2]: Hepatology Journal Review on Tigecycline Hepatotoxicity
[3]: Drug Safety Study on BSEP Inhibition
[4]: Pharmacokinetics in Liver Models
[5]: IDSA Guidelines for Monitoring
[6]: ClinicalTrials.gov TYGACIL Data
[7]: Eravacycline vs Tigecycline Comparison